Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck Receives Approval for Dulera

By Drug Discovery Trends Editor | June 24, 2010

WHITEHOUSE STATION, N.J. (AP) – Merck & Co. said it received marketing approval for its asthma treatment Dulera, but the drug will come with a serious warning that it can increase risk of death.

The Food and Drug Administration cleared Dulera, which comes in an inhaler, for use in patients 12 and older, the company said.

Dulera, which combines two types of medication, is meant only for patients with poorly controlled asthma. That’s because of the slight risk that one component – formoterol fumarate, part of the drug class called long-acting beta agonists – could cause asthma-related death. These drugs relax muscles around stressed airways, which could keep patients from noticing dangerous inflammation building up in their airways.

The FDA is mandating that Dulera carry its strongest warning, in a black box in the detailed package insert, as is required for four asthma medicines in the same class: Advair, Symbicort, Foradil and Serevent.

Earlier this month, the agency strengthened rules it announced in February for all long-acting beta agonists, or LABAs. Besides carrying the warning about risk of death, these drugs are to be used along with an inhaled corticosteroid. Also, patients should use LABAs only until asthma control is achieved and maintained, then gradually stop using them.

Dulera’s second component is an inhaled corticosteroid, mometasone furoate, for reducing airway inflammation. That drug is sold under the brand name Asmanex as an allergy treatment. It was developed by Schering-Plough Corp., which Merck bought last November.

Merck said Dulera should be available around the country by the end of July, in two strengths.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50